Showing results (1171-1180 of 6,501) with videos related to

Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|January 10, 2022
Functional virus-specific memory T cells survey glioblastomaJianfang Ning, Noah V Gavil, Shaoping Wu, et al.
Cancer Immunology, Immunotherapy : CII|January 19, 2022
Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinomaWenhao Xu, Chunguang Ma, Wangrui Liu, et al.
Cancer Immunology, Immunotherapy : CII|November 28, 2021
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabMathilde Bureau, Thierry Chatellier, Tanguy Perennec, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2T Nishimura, Y Togashi, M Goto, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563R Maekawa, M Matsumoto, T Kitagawa, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized miceR A De Weger, B Wilbrink, R M Moberts, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cellsT Yoshioka, H Fujiwara, Y Takai, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clonesH Fujiwara, S Sato, A Kosugi, et al.
Cancer Immunology, Immunotherapy : CII|January 5, 2022
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agentsCarlos Zamora Atenza, Geòrgia Anguera, Mariona Riudavets Melià, et al.
Cancer Immunology, Immunotherapy : CII|January 6, 2022
Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallengeHee Yeon Kim, Jae-Hyeog Choi, Md Masudul Haque, et al.
Pageof 651